非洲17国急性心力衰竭的病因、管理与结局:THESUS-HF II前瞻性多中心观察性队列研究
THESUS-HF II在17个非洲国家50家医院前瞻性纳入1578例急性心衰成人患者,评估病因、治疗模式、就诊率及180天结局。
核心结论
- THESUS-HF II提示非洲急性心衰病因谱较THESUS-HF有所演变,但诊断能力与确认方式差异可能影响比较。
- 该相对年轻队列死亡率较高,凸显心衰预防、心脏专科可及性、指南指导治疗和出院后随访的重要性。
- 短期急性心衰结局似乎不由人口学、病因学和超声心动图因素驱动。
研究设计与样本
- THESUS-HF II为前瞻性、多中心、观察性队列研究,在17个非洲国家50家医院开展。
- 纳入18岁及以上急性心衰成人患者,在8周内7个24小时监测期入组,共1578例进入队列。
- 急性心衰由急性呼吸困难伴淤血识别,辅以心电图、胸片和床旁超声心动图支持。
- 研究评估成人 catchment 人群每周每万人就诊率、治疗模式、再入院和至180天全因死亡。
- 研究注册于泛非临床试验注册中心(PACTR202410553810557)。
关键数值与推荐
- 达到目标剂量的患者不足半数。
临床怎么用
- 非洲急性心衰患者应优先排查高血压性心脏病、心肌病和缺血性心脏病。
- 出院时应积极启用并滴定指南指导药物,包括RAAS抑制剂、β受体阻滞剂、MRA和SGLT2抑制剂。
- 需加强出院后随访以降低180天高死亡率,并关注失访问题。
局限性
- 诊断能力与确认方式差异可能影响病因谱比较。
- 观察性设计无法确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contemporary data on the aetiology, management, and outcomes of acute heart failure across Africa are scarce. We aimed to conduct a contemporary assessment of acute heart failure aetiology, treatment patterns, presentation rates, and 180-day outcomes across Africa. METHODS: THESUS-HF II was a prospective, multicentre, observational cohort study in 50 hospitals across 17 African countries. Adults aged 18 years or older with acute heart failure were enrolled during seven 24 h surveillance periods within an 8-week, site-specific window. Acute heart failure was identified by acute dyspnoea and congestion, supported by electrocardiography, chest radiography, and point-of-care echocardiography. We assessed presentation rates per 10 000 people in the adult catchment population per week, treatment patterns (including medication use at discharge), readmission, and all-cause mortality through to 180 days. This study was registered with the Pan African Clinical Trial Registry (PACTR202410553810557) and is completed; however, substudies are ongoing. FINDINGS: Between July 1, 2024, and July 31, 2025, 1741 patients were assessed for eligibility at participating hospitals and 1578 were included in the study cohort. 793 (50·5%) of 1570 participants were female, 777 (49·5%) were male, and 1533 (97·8%) of 1567 were of African descent; median age was 56·0 years (IQR 40·0-69·0). The weekly acute heart failure presentation rate was 0·03 per 10 000 people (95% CI 0·02-0·05) overall and 0·02 per 10 000 people (0·01-0·04) for de novo acute heart failure. De novo acute heart failure accounted for 1007 (64·2%) of 1568 presentations. The leading aetiologies were hypertensive heart disease (576 [36·5%] of 1578), cardiomyopathy (370 [23·4%]), and ischaemic heart disease (367 [23·3%]). Median hospital ward stay was 6·0 days (IQR 4·0-10·0), and in-hospital mortality was 8·7% (95% CI 7·3-10·2; 134 of 1542 patients). At discharge, renin-angiotensin-aldosterone system inhibitors were prescribed in 1014 (73·9%) of 1373 patients, β blockers in 1053 (76·9%) of 1369 patients, mineralocorticoid receptor antagonists in 982 (71·9%) of 1366, and SGLT2 inhibitors in 743 (54·7%) of 1359; target doses were reached in fewer than half of patients. Of 1567 patients included in time-to-event analyses, 528 (33·7%) were lost to follow-up before 180 days. All-cause mortality was 11·1% (95% CI 9·6-12·9; 160 deaths) at 30 days and 20·6% (18·4-23·0; 255 deaths) at 180 days. All-cause mortality did not differ across aetiological groups over 30 days (log-rank p=0·39), but differed over 180 days (p=0·019). INTERPRETATION: Compared with THESUS-HF, THESUS-HF II suggests an evolving aetiological profile of acute heart failure in Africa, although differences in ascertainment and diagnostic capability might have contributed to the apparent aetiological shift. High mortality in this relatively young cohort highlights the importance of heart failure prevention, access to cardiac care, guideline-directed therapy, and post-discharge follow-up. These findings suggest that short-term acute heart failure outcomes are not driven by its demographic, aetiological, and echocardiographic factors. FUNDING: Cape Heart Institute, University of Cape Town; Hippocrate Foundation; The Heart Initiative; and Pan African Society of Cardiology.
引用
- Sliwa K, Hahnle J, Stewart S, et al. Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II): a prospective, multicentre, observational cohort study. Lancet. 2026. PMID: 42669305. doi:10.1016/S0140-6736(26)01657-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。